Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice.
Florine SeidelRobert KleemannWim van DuyvenvoordeNikki van TrigtNanda KeijzerSandra van der KooijCees van KootenLars VerschurenAswin L MenkeAmanda J KiliaanJohnathan WinterTimothy R HughesBryan Paul MorganFrank BaasKees FluiterMartine C MorrisonPublished in: International journal of molecular sciences (2022)
We show, for the first time, that treatment with an anti-C5 antibody in advanced stages of NASH is not sufficient to reduce the disease, while therapeutic intervention against established atherosclerosis is beneficial to limit further progression.